Management of breast cancer brain metastases: Focus on human epidermal growth factor receptor 2-positive breast cancer
After the introduction of trastuzumab, a monoclonal antibody that binds to human epidermal growth factor receptor 2 (HER2), the overall survival (OS) among patients with HER2-positive breast cancer has been substantially improved. However, among these patients, the incidence of brain metastases (BM)...
Saved in:
Main Authors: | Peng Yuan, Song-Lin Gao |
---|---|
Format: | article |
Language: | EN |
Published: |
KeAi Communications Co., Ltd.
2017
|
Subjects: | |
Online Access: | https://doaj.org/article/b7d0348f3a6843e9a2eea76808764af7 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Use of comorbidity indices in patients with any cancer, breast cancer, and human epidermal growth factor receptor-2-positive breast cancer: A systematic review.
by: Maribel Salas, et al.
Published: (2021) -
Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer
by: Yardley DA
Published: (2016) -
Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer
by: Siavash Jabbari, et al.
Published: (2011) -
Optimal management of bone metastases in breast cancer patients
by: Wong MH, et al.
Published: (2011) -
Emerging role of brain metastases in the prognosis of breast cancer patients
by: Hambrecht A, et al.
Published: (2011)